Favorable Preliminary Outcomes for Men with Low- and Intermediate-Risk Prostate Cancer Treated with 19 Gy Single Fraction High-Dose-Rate Brachytherapy

Publication date: Available online 9 November 2016
Source:International Journal of Radiation Oncology*Biology*Physics
Author(s): Daniel J. Krauss, Hong Ye, Alvaro A. Martinez, Beth Mitchell, Evelyn Sebastian, Amy Limbacher, Gary S. Gustafson
PurposeTo report toxicity and preliminary clinical outcomes of a prospective trial evaluating 19 Gy single fraction high-dose-rate (HDR) brachytherapy for men with low- and intermediate-risk prostate cancer.Materials and Methods63 patients were treated according to an IRB-approved prospective study of single fraction HDR brachytherapy. Eligible patients had tumor stage < T2a, PSA < 15, and Gleason score < 7. Patients with prostate gland volume > 50 cc and baseline American Urologic Association (AUA) symptom score > 12 were ineligible. Patients underwent trans-rectal ultrasound (TRUS)-guided trans-perineal implant of the prostate followed by single fraction HDR brachytherapy. Treatment was delivered via Ir-192 to a dose of 19 Gy prescribed to the prostate with no additional margin applied.Results58 patients were available for analysis. Five withdrew consent during the follow-up period. Median follow up was 2.9 years [range 0.3-5.2 years]. Median age was 61.4 years. Median gland volume at the time of treatment was 34.8 cc. 91% of patients had T1 disease, 71% had Gleason score < 6 (29% Gleason 7), and median pre-treatment PSA was 5.1 ng/mL. Acute and chronic grade 2 genitourinary toxicity incidence was 12.1% and 10.3%, respectively. No grade 3 urinary toxicity occurred. No patients experienced acute rectal toxicity > grade 2, and 2 experienced > grade 2 chronic GI toxicity. 3 patients have experienced biochemical failure yielding a 3-year cumulative incidence estimate of 6.8%.ConclusionsSingle fraction HDR brachytherapy is well-tolerated with favorable preliminary biochemical and clinical disease control rates.

Teaser

We present results of a prospective, non-randomized clinical trial of 19 Gy single-fraction HDR brachytherapy for low- and intermediate-risk prostate cancer patients. With 58 patients and a median follow up of nearly 3 years, we have demonstrated favorable biochemical control rates and a highly favorable toxicity profile. These results support further prospective study in this area.


http://rss.sciencedirect.com/action/redirectFile?&zone=main&currentActivity=feed&usageType=outward&url=http%3A%2F%2Fwww.sciencedirect.com%2Fscience%3F_ob%3DGatewayURL%26_origin%3DIRSSSEARCH%26_method%3DcitationSearch%26_piikey%3DS0360301616330966%26_version%3D1%26md5%3D8d1641e91a2fd11153e03d632d1c29a0